Aptose Financial Statements From 2010 to 2025

APTO Stock  USD 3.76  0.03  0.79%   
Aptose Biosciences financial statements provide useful quarterly and yearly information to potential Aptose Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aptose Biosciences financial statements helps investors assess Aptose Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aptose Biosciences' valuation are summarized below:
Market Capitalization
8.1 M
Earnings Share
(87.60)
We have found one hundred twenty available fundamental signals for Aptose Biosciences, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Aptose Biosciences' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 94.3 M, while Enterprise Value is likely to drop about 15.3 M.
Check Aptose Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptose Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 75.2 K, Interest Expense of 929.8 K or Selling General Administrative of 18.8 M, as well as many indicators such as Price To Sales Ratio of 185, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Aptose financial statements analysis is a perfect complement when working with Aptose Biosciences Valuation or Volatility modules.
  
Check out the analysis of Aptose Biosciences Correlation against competitors.
To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.

Aptose Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets28.5 M14.9 M31.8 M
Slightly volatile
Other Current Liabilities10.7 M10.2 M3.7 M
Slightly volatile
Total Current Liabilities18.4 M17.6 M6.2 M
Slightly volatile
Property Plant And Equipment Net1.3 M1.3 M654.4 K
Slightly volatile
Accounts Payable7.3 MM2.3 M
Slightly volatile
Cash15.8 M10.6 M23.3 M
Slightly volatile
Non Current Assets Total1.7 M985.5 K705.9 K
Slightly volatile
Cash And Short Term Investments10.1 M10.6 M28.9 M
Slightly volatile
Common Stock Shares Outstanding8.2 M7.8 M3.1 M
Slightly volatile
Liabilities And Stockholders Equity28.5 M14.9 M31.8 M
Slightly volatile
Other Current Assets3.2 MM1.3 M
Slightly volatile
Other Stockholder Equity35.8 M64.9 M37.6 M
Slightly volatile
Total Liabilities19.2 M18.3 M6.6 M
Slightly volatile
Property Plant And Equipment Gross4.7 M4.5 M1.1 M
Slightly volatile
Total Current Assets26.2 M13.7 M31.1 M
Slightly volatile
Common Stock537.1 M511.5 M298.1 M
Slightly volatile
Property Plant Equipment364.1 K189.9 K359.8 K
Slightly volatile
Short and Long Term Debt Total867.8 K913.5 K1.6 M
Slightly volatile
Capital Surpluse51.4 M79.2 M42.8 M
Slightly volatile
Capital Stock435.6 M511.5 M338.2 M
Slightly volatile
Long Term Debt Total808.8 K909.9 K992 K
Slightly volatile
Capital Lease Obligations879.7 K913.5 K1.3 M
Slightly volatile
Non Current Liabilities Other808.8 K909.9 K992 K
Slightly volatile

Aptose Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization75.2 K79.2 K213.1 K
Pretty Stable
Selling General Administrative18.8 M17.9 M10.4 M
Slightly volatile
Other Operating Expenses63.2 M60.2 M28.8 M
Slightly volatile
Research Development44.4 M42.3 M18.3 M
Slightly volatile
Total Operating Expenses63.2 M60.2 M28.8 M
Slightly volatile
Selling And Marketing Expenses162.7 K171.2 K155.6 K
Pretty Stable
Interest Income1.7 M1.6 M874.9 K
Very volatile
Net Interest Income1.7 M1.6 M469.5 K
Slightly volatile
Reconciled Depreciation472.1 K524.4 K286.8 K
Slightly volatile
Non Operating Income Net Other488.6 K895.9 K393.5 K
Slightly volatile

Aptose Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow44.6 M42.5 M26.1 M
Slightly volatile
Other Cashflows From Financing Activities31.7 K33.4 KM
Very volatile
Depreciation654.2 K419.4 K299.4 K
Slightly volatile
Total Cash From Financing Activities15.3 M7.9 M18.5 M
Pretty Stable
End Period Cash Flow15.8 M10.6 M23.3 M
Slightly volatile
Stock Based Compensation3.8 M4.2 M3.9 M
Slightly volatile
Issuance Of Capital Stock5.2 M5.5 M25 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio185195184
Slightly volatile
Invested Capital21.4 M24 M26.2 M
Slightly volatile
Average Payables322.3 K339.3 K387 K
Slightly volatile
Capex To Depreciation0.05320.0561.3234
Slightly volatile
EV To Sales188198186
Slightly volatile
Sales General And Administrative To Revenue47.1127.5626.5466
Pretty Stable
Research And Ddevelopement To Revenue20.9922.120.1169
Pretty Stable
Capex To Revenue0.01670.01760.1395
Slightly volatile
Cash Per Share1.51.5890.5443
Slightly volatile
Income Quality0.620.780.7772
Pretty Stable
Tangible Asset Value21 M23.6 M25.7 M
Slightly volatile
Current Ratio0.670.77.4729
Pretty Stable
Receivables Turnover0.40.450.4906
Slightly volatile
Capex Per Share0.00470.00491.3461
Slightly volatile
Revenue Per Share5.052.743.2424
Slightly volatile
Interest Debt Per Share0.160.1716.7169
Slightly volatile
Debt To Assets0.08540.08990.1346
Slightly volatile
Operating Cycle584657716
Slightly volatile
Ebt Per Ebit0.620.880.9604
Slightly volatile
Long Term Debt To Capitalization0.02060.02170.045
Slightly volatile
Quick Ratio0.670.77.4729
Pretty Stable
Net Income Per E B T0.790.880.9626
Slightly volatile
Cash Ratio0.520.555.1152
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.171.151.0287
Slightly volatile
Fixed Asset Turnover0.840.80.837
Slightly volatile
Debt Ratio0.08540.08990.1346
Slightly volatile
Price Sales Ratio185195184
Slightly volatile
Asset Turnover0.05380.05120.0534
Slightly volatile
Gross Profit Margin1.041.189.5334
Slightly volatile

Aptose Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap94.3 M48.2 M83.5 M
Slightly volatile
Enterprise Value15.3 M16.1 M52.9 M
Pretty Stable

Aptose Fundamental Market Drivers

Cash And Short Term Investments9.3 M

Aptose Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aptose Biosciences Financial Statements

Aptose Biosciences investors utilize fundamental indicators, such as revenue or net income, to predict how Aptose Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.3 M-2.2 M
Cost Of Revenue545.7 K573 K
Sales General And Administrative To Revenue 27.56  47.11 
Research And Ddevelopement To Revenue 22.10  20.99 
Capex To Revenue 0.02  0.02 
Revenue Per Share 2.74  5.05 
Ebit Per Revenue(38.56)(40.48)

Pair Trading with Aptose Biosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptose Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptose Biosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aptose Stock

  0.83ME 23Andme HoldingPairCorr

Moving against Aptose Stock

  0.83DVAX Dynavax TechnologiesPairCorr
  0.64VALN Valneva SE ADRPairCorr
  0.48VIGL Vigil NeurosciencePairCorr
  0.34DTIL Precision BioSciences Earnings Call This WeekPairCorr
  0.31DMAC DiaMedica TherapeuticsPairCorr
The ability to find closely correlated positions to Aptose Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptose Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptose Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptose Biosciences to buy it.
The correlation of Aptose Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptose Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptose Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptose Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock:
Check out the analysis of Aptose Biosciences Correlation against competitors.
To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(87.60)
Return On Assets
(1.42)
Return On Equity
(6.94)
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.